Benitec Biopharma Inc.
BNTC
$13.75
$0.1050.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 7.00K | 61.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 7.00K | 61.00K |
| Cost of Revenue | -3.00K | -2.00K | -108.00K | -108.00K | -105.00K |
| Gross Profit | 3.00K | 2.00K | 108.00K | 115.00K | 166.00K |
| SG&A Expenses | 9.36M | 7.64M | 6.99M | 6.32M | 5.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.09M | 22.41M | 22.49M | 21.50M | 21.75M |
| Operating Income | -24.09M | -22.41M | -22.49M | -21.49M | -21.69M |
| Income Before Tax | -21.42M | -20.86M | -21.75M | -21.69M | -21.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.42 | -20.86 | -21.75 | -21.69 | -21.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.42M | -20.86M | -21.75M | -21.69M | -21.81M |
| EBIT | -24.09M | -22.41M | -22.49M | -21.49M | -21.69M |
| EBITDA | -24.00M | -22.31M | -22.40M | -21.41M | -21.60M |
| EPS Basic | -3.04 | -5.35 | -7.92 | -10.15 | -11.19 |
| Normalized Basic EPS | -1.86 | -3.30 | -4.73 | -6.17 | -6.81 |
| EPS Diluted | -3.04 | -5.35 | -7.92 | -10.15 | -11.19 |
| Normalized Diluted EPS | -1.86 | -3.30 | -4.73 | -6.17 | -6.81 |
| Average Basic Shares Outstanding | 44.23M | 24.73M | 16.24M | 8.99M | 8.02M |
| Average Diluted Shares Outstanding | 44.23M | 24.73M | 16.24M | 8.99M | 8.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |